ArticleAntimicrobial agents and chemotherapy1992
In vitro study of anticancer acridines as potential antitrypanosomal and antimalarial agents.
Article in Antimicrobial agents and chemotherapy, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 56 citations in OpenAlex.
- Experiments and Calculation on New N,N-Molecules (Basel, Switzerland) · 2024Article
- Curvicollide D Isolated from the FungusInternational journal of molecular sciences · 2022Article
- Article
- Application of a novel microtitre plate-based assay for the discovery of new inhibitors of DNA gyrase and DNA topoisomerase VI.PloS one · 2013Article
- Synthesis and anti-intestinal nematode activity of variously substituted benzonaphthyridine derivatives.Molecules (Basel, Switzerland) · 2011Article
- Acridine and acridinones: old and new structures with antimalarial activity.The open medicinal chemistry journal · 2011Article
- Drug targets in Leishmania.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2010Article
- Antimalarial 9-anilinoacridine compounds directed at hematin.Antimicrobial agents and chemotherapy · 2003Article
- Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi.Antimicrobial agents and chemotherapy · 1996Article
- 9-Anilinoacridines as potential antileishmanial agents.Antimicrobial agents and chemotherapy · 1993Article
- Structure-activity relationships and modes of action of 9-anilinoacridines against chloroquine-resistant Plasmodium falciparum in vitro.Antimicrobial agents and chemotherapy · 1993Article
- Hypothesis: The potential application of doxorubicin against cutaneous leishmaniasis.Tropical parasitologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The requirement for rational drug design in the search for new agents that are active against parasitic protozoa prompted our in vitro studies with a group of 9-anilinoacridines. In vitro growth assays with Trypanosoma lewisi identified a series of C-1' alkylaminoacridines which possess previously unreported potent growth-inhibitory activities against T. lewisi at a concentration range of 0.1 to 1 microM. In contrast, several 9-anilinoacridines that possess acridine ring NH2 substituents at C-3 and C-6 were inactive against T. lewisi, but they possessed strong activity against Plasmodium falciparum at a concentration range of 0.1 to 2.8 microM. In mammalian cells, amsacrine [4'-(9-acridinylamino)methanesulfon-m-anisidide] inhibits DNA topoisomerase II; however, amsacrine was only weakly active against T. lewisi. Such differences in the patterns of susceptibility of mammalian cells, T. lewisi, and P. falciparum to these 9-anilinoacridines may reflect enzyme differences between different parasites and mammalian cells that can be exploited by further improvements in drug design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.